

30th July 2026

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

1) Service Context & Care Pathway:

- a) Does your Trust diagnose and/or treat patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?**

Yes.

- b) If yes, which clinical departments or specialties are responsible for CIDP diagnosis and management? (e.g., Neurology, Neurophysiology, Immunology, Specialist Neuromuscular Services).**

At East Sussex Healthcare NHS Trust (ESHT), diagnosis and management of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) are primarily undertaken by the Neurology department, which is responsible for clinical assessment, diagnosis, and ongoing management.

Neurophysiology Sussex (Brighton) - provides diagnostic investigations such as nerve conduction studies. This service sits within University Hospitals Sussex NHS Foundation Trust. Their contact details are as follows:

By email: UHSussex.foi@nhs.net

Where clinically indicated, input may also be sought from:

- General Medicine - particularly for inpatient care and monitoring
- Immunology (via referral/pathways) - for advice on immunomodulatory treatment if required

- c) Does your Trust operate a specialist neuromuscular or neuroimmunology service?

No.

If so, please provide a brief description (e.g., staffing, catchment area, referral pathways).

Not applicable, ESHT does not operate a dedicated specialist neuromuscular or neuroimmunology service. Patients requiring highly specialised input may be referred to tertiary centres.

2) CIDP Patient Numbers:

- a) How many patients with a confirmed diagnosis of CIDP are currently recorded within your Trust?

- Please provide the most recent 12-month period available.

Please note that East Sussex Healthcare NHS Trust (ESHT) does not centrally record the numbers of patients with a diagnosis of CIDP (ICD-10 code G61.81). ESHT does record centrally patients with a diagnosis of 'Other Inflammatory Polyneuropathies' (ICD-10 code G61.8) and the current figures for these patients are:

Diagnosis Code	Diagnosis Description	Number of Patients with a Primary Diagnosis	Number of Patients with a Secondary Diagnosis	Total Number of Patients
G61.8	Other Inflammatory Polyneuropathies	256	9	265

- b) If available, please provide the number of newly diagnosed CIDP patients in the same period.

Please see the response to question 2a.

- c) If diagnosis data are coded, please confirm which coding system is used (e.g., ICD 10, SNOMED CT).

Please see the response to question 2a.

3) CIDP Treatment With IVIg:

The figures below are for patients with 'Other inflammatory polyneuropathies' (G61.8). Please see the response to question 2a for further information.

- a) **How many CIDP patients received intravenous immunoglobulin (IVIg) at your Trust in the most recent 12-month period?**

11.

- b) **Please provide the number of IVIg treatment episodes administered to CIDP patients in that period.**

190.

- c) **If available, please provide the total volume (grams) of IVIg used for CIDP during the same period.**

675 grams.

- d) **How many CIDP patients received IVIg vs SCIg in the most recent 12-month period?**

There has been no SCIg issued in the past 12 months.

- e) **If SCIg is used, please provide the number of treatment episodes and total grams administered.**

None.

- f) **If available, please provide typical dosing regimens used for CIDP (e.g., grams/kg and treatment intervals).**

Not applicable.

- g) **If recorded, please provide the average number of IVIg cycles per CIDP patient per year.**

ESHT does not hold this information as it is not recorded.

3) Operational & Capacity Information:

- a) **Does your Trust have a formal protocol or clinical guideline for the diagnosis and management of CIDP?**

ESHT does not hold a Trust-specific standalone protocol exclusively for the diagnosis and management of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

- b) **If yes, please provide a copy or link.**

Not applicable.

- c) **Does your Trust operate a waiting list for IVIg treatment?**

There is no waiting list. Referrals are made to the Infusion Unit. Appointments are then booked in line with available capacity – usually within two weeks.

- d) **If yes, please provide the current number of patients waiting and the average waiting time.**

Not applicable.

Does your Trust participate in any regional or national neuromuscular networks relevant to CIDP?

ESHT participates in regional neurology networks, including referrals to tertiary neuroscience centres for specialist neuromuscular input.

- e) **Does your Trust record adverse events or complications associated with IVIg administration in CIDP patients?**

ESHT records adverse events associated with IVIg administration as part of standard clinical governance and medicines safety monitoring processes.

This includes reporting via:

- Local incident reporting systems.
- MHRA Yellow Card Scheme where appropriate.
- Pharmacy and transfusion/immunoglobulin governance oversight.

- f) **If yes, please provide any available summary data.**

Not applicable, as no adverse events or complications associated with IVIg administration in CIDP patients have been reported on the Trust's incident reporting system.

4) Commissioning, Governance & Funding:

- a) **Which commissioning arrangements apply to CIDP treatment at your Trust? (e.g., specialised commissioning, local ICB commissioning)**

NHS England specialised commissioning arrangements for immunoglobulin therapies.

- b) **Does your Trust use a prior approval or funding request process for IVIg in CIDP?**

ESHT uses a prior approval process for IVIg in CIDP.

- c) **Does your Trust participate in the National Immunoglobulin Database (NID)?**

Yes.

- d) **If yes, do you routinely submit CIDP specific data?**

ESHT participates in the National Immunoglobulin Database (NID) as part of national requirements for IVIg prescribing, tracking, and governance, and the relevant data is submitted routinely.

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
East Sussex Healthcare NHS Trust
0300 131 4716
Core Hours of Business: Monday to Friday 9.00am to 4.00pm